Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy
ChemBioChem · 2025
DOI: 10.1002/cbic.202400599 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemBioChem, 2025. Verfasst von Yihao Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, The Key Laboratory of Chemical Biology of Fujian Province, State Key Laborato…. Hauptthemen laut MEDLINE: Immunotherapy, Aptamers, Nucleotide, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: Ministry of Science and Technology of China, National Natural Science Foundation of China, Scientific Research Foundation of Xiang An Biomedicine Laboratory.
Abstract (Originalsprache)
Cancer has long been a significant threat to human life and health. The advent of immune checkpoint blockade strategies has reversed cancer‐induced immune suppression, advanced the development of immunotherapy, and offered new hope in the fight against cancer. Aptamers, which possess the same specificity and affinity as antibodies, are advantageous due to their synthetic accessibility and ease of modification, providing novel insights for immune checkpoint research. In this review, we outline the key aptamers currently developed for immune checkpoints such as CTLA‐4, PD‐1, PD−L1 and Siglec‐15. We explore their potential in therapeutic strategies, including functionalizing or engineering aptamers for covalent binding, valency control, and nanostructure assembly, as well as investigating molecular mechanisms such as glycosylated protein functions and cell‐cell interactions. Finally, the future applications of aptamers in immunotherapy are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, The Key Laboratory of Chemical Biology of Fujian Province, State Key Laboratory of Physical Chemistry of Solid Surfaces, Department of Chemical Bio…
- Renji Hospital, School of medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
ORCID-Profile: Yanling Song
Förderung
- Ministry of Science and Technology of China
- National Natural Science Foundation of China
- Scientific Research Foundation of Xiang An Biomedicine Laboratory
- Program for Changjiang Scholars
- Innovative Research Team in University
Zitieren
APA
Huang, Y., Lin, G., Liu, S., Chen, M., Yang, C., & Song, Y. (2025). Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy. ChemBioChem. https://doi.org/10.1002/cbic.202400599
Vancouver
Huang Y, Lin G, Liu S, Chen M, Yang C, Song Y. Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy. ChemBioChem. 2025. doi:10.1002/cbic.202400599
BibTeX
@article{Huang2025,
author = {Huang, Yihao and Lin, Guihong and Liu, Sinong and Chen, Mingying and Yang, Chaoyong and Song, Yanling},
title = {Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy},
journal = {ChemBioChem},
year = {2025},
doi = {10.1002/cbic.202400599}
}
EUVIMED